Patents
Literature
2 results about "Cardiac hypertrophy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cardiac hypertrophy. enlargement of the heart coincident with an increase in muscle mass; an indication of response to an increase in load which may or may not be associated with disease. It is an expression of cardiac compensation but some of the cardiac reserve has been lost.
Use of a small molecule compound KA-C1 in the preparation of a medicament
PendingCN122097353AOrganic active ingredientsCardiovascular disorderCardiac fibrosisProtein activity
The application belongs to the field of medicine, and specifically discloses application of a small molecule compound KA-C1 in preparation of a medicine for preventing or treating cardiac hypertrophy, cardiac fibrosis and / or heart failure. The application finds that kynurenine-3-monooxygenase (KMO) is an effective medicine target for treating pathological cardiac hypertrophy and cardiac fibrosis through research. Through computer-aided virtual screening, the application finds a KMO-specific agonist KA-C1, and KA-C1, as a medicine active ingredient, can directly stimulate KMO protein activity, thereby effectively resisting pathological cardiac hypertrophy and cardiac fibrosis, and further preventing or treating heart failure. Therefore, the discovery of the small molecule compound KA-C1 provides a new medicine target strategy for treating pathological cardiac hypertrophy, cardiac fibrosis and heart failure, and has important and wide application prospects.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV
1,2,3,4,6-o-galloylglucose for use in the preparation of a medicament for the prevention and / or treatment of cardiac hypertrophy
The application discloses application of 1,2,3,4,6-O-galloyl glucose in preparation of a drug for preventing and / or treating myocardial hypertrophy, and belongs to the technical field of biological medicine. The application proves for the first time that PGG can significantly improve cardiac dysfunction induced by TAC operation, inhibit increase of heart volume and weight, myocardial cell hypertrophy, down-regulate expression of myocardial hypertrophy markers Nppa, Nppb and Myh7, and block excessive activation of an AKT / ERK signal path. Therefore, PGG can effectively prevent and / or treat pathological myocardial hypertrophy, and has a clear clinical application prospect.
Owner:FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV